Details for New Drug Application (NDA): 206144
✉ Email this page to a colleague
NDA 206144 describes CEFIXIME, which is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, Belcher, and Chartwell Rx, and is included in six NDAs. It is available from six suppliers. Additional details are available on the CEFIXIME profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the cefixime profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Summary for 206144
| Tradename: | CEFIXIME |
| Applicant: | Chartwell Rx |
| Ingredient: | cefixime |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 206144
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | 100MG/5ML | ||||
| Approval Date: | Nov 17, 2017 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | 200MG/5ML | ||||
| Approval Date: | Nov 17, 2017 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
